Neogen Reports Mixed Q3, Raises FY26 Revenue Outlook, and Divests Genomics Business for $160M

summarizeSummary

Neogen reported mixed Q3 results with a wider GAAP net loss but improved adjusted EBITDA margins, while raising its full-year revenue guidance and announcing the divestiture of its Genomics business for $160 million to reduce debt.

check_boxKey Events

• Mixed Q3 Financials Reported

  Neogen reported a Q3 net loss of $17.0 million (EPS $(0.08)), wider than the prior year, with overall revenue down 4.4%. However, adjusted net income was $19.4 million (EPS $0.09) and adjusted EBITDA margin improved to 22.8%.

• Genomics Business Divested for $160M

  The company entered a definitive agreement to sell its global Genomics business to Zoetis Inc. for $160.0 million. Net proceeds of approximately $140.0 million are expected to be used for debt reduction, with the transaction anticipated to close by Q2 FY2027.

• FY2026 Revenue Guidance Raised

  Neogen increased its fiscal year 2026 revenue outlook to $857 million - $860 million, up from the previous guidance of $845 million - $855 million, while maintaining its Adjusted EBITDA guidance.

• Animal Safety Segment Faces Supplier Challenges

  The Animal Safety segment experienced a 20.1% revenue decrease (8.7% core decline) in Q3 due to third-party supplier issues, predominantly impacting U.S. sales.

auto_awesomeAnalysis

Neogen's third-quarter results presented a mixed picture, with a widening GAAP net loss and a significant decline in the Animal Safety segment due to supplier issues. However, the company demonstrated resilience with improved adjusted EBITDA margins and strong core growth in its Food Safety segment. The most impactful news is the strategic divestiture of its global Genomics business for $160 million, which is expected to generate approximately $140 million in net proceeds to significantly reduce debt and improve the company's financial leverage. Furthermore, the company raised its fiscal year 2026 revenue guidance, signaling confidence in future performance despite current challenges. This proactive strategic realignment and positive outlook on revenue are key takeaways for investors.